Drug Trial Radar · NCT06810804
A Phase IIa Study to Evaluate NBQ72S
Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Apr 22, 2025
Primary completion
Aug 31, 2026
Study completion Feb 28, 2027
Sponsor
- Lead sponsor
- Nantong Bencao Quadriga Medical Technology Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase IIa, single-arm, open-label study was conducted to evaluate the efficacy and safety of NBQ72S, in patients with leptomeningeal metastases from breast cancer. All patients will receive the study drug every 28 days until withdrawal from treatment.
Conditions
- Breast Cancer
Interventions
NBQ72SDrug
Patients will receive the study drug every 28 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- OSTime frame: through study completion, an average of 1.5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.